Acomplia (also known as Rimonabant) is a selective CB1 endocannabinoid receptor blocker used for treating obesity, overweight as well as nicotine addiction. Accomplia is by far the first selective CB1 receptor antagonist approved for use all over the world. In Europe and the US, Accomplia is used together with a diet and exercise program for treating individuals who suffer from overweight, obesity or associated risk factors, such as dyslipidaemia or type 2 diabetes.

Acomplia is a brain-child of French pharmaceutical company Sanofi-Aventis considered as an experimental drug that offers the promise of helping people lose weight and quit smoking simultaneously. This anti smoking diet pill works by blocking the CB1 receptors of the brain commonly called the ‘pleasure centre’ and interfering with the cycle of craving and satisfaction thus making hunger or cigarette pangs more manageable. Some analysts have also started considering Acomplia Rimonabant as a heart drug.

Results of a University of Toronto study have shown that respondents who believed themselves to be overweight were 50% more likely to be smokers than others. Just as nicotine is believed to help speed up metabolism, quitting smoking may lead to weight gain even if you are not eating more. Acomplia, (generic name Rimonabant) is a nicotine patch and weight loss product combined in one pill. It is created to help people stop both food and cigarette cravings.

For treating overweight or obesity you have two major options: dietary measures including pills and supplements and daily physical workouts. The best way to lose weight considerably and effectively however is to combine both. Anorexiants or weight loss supplements should be taken in consonance with proper fat free diet and a strict workout schedule. Some popular weight loss supplements on the market: Accomplia, Amphetamines, Orlistat, Sympathomimetics, Meredia, Trexan.